MicroRNAs Expression in Response to rhNGF in Epithelial Corneal Cells: Focus on Neurotrophin Signaling Pathway.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
25 Mar 2022
Historique:
received: 14 02 2022
revised: 21 03 2022
accepted: 21 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 14 4 2022
Statut: epublish

Résumé

Nerve growth factor efficacy was demonstrated for corneal lesions treatment, and recombinant human NGF (rhNGF) was approved for neurotrophic keratitis therapy. However, NGF-induced molecular responses in cornea are still largely unknown. We analyzed microRNAs expression in human epithelial corneal cells after time-dependent rhNGF treatment. Nearly 700 microRNAs were analyzed by qRT-PCR. MicroRNAs showing significant expression differences were examined by DIANA-miRpath v.3.0 to identify target genes and pathways. Immunoblots were performed to preliminarily assess the strength of the in silico results. Twenty-one microRNAs (miR-26a-1-3p, miR-30d-3p, miR-27b-5p, miR-146a-5p, miR-362-5p, mir-550a-5p, mir-34a-3p, mir-1227-3p, mir-27a-5p, mir-222-5p, mir-151a-5p, miR-449a, let7c-5p, miR-337-5p, mir-29b-3p, miR-200b-3p, miR-141-3p, miR-671-3p, miR-324-5p, mir-411-3p, and mir-425-3p) were significantly regulated in response to rhNGF. In silico analysis evidenced interesting target genes and pathways, including that of neurotrophin, when analyzed in depth. Almost 80 unique target genes (e.g., MicroRNA levels in response to rhNGF were for the first time analyzed in corneal cells. Novel insights about microRNAs, target genes, pathways modulation, and possible biological responses were provided. Importantly, given the putative role of microRNAs as biomarkers or therapeutic targets, our results make available data which might be potentially exploitable for clinical applications.

Identifiants

pubmed: 35408969
pii: ijms23073597
doi: 10.3390/ijms23073597
pmc: PMC8998691
pii:
doi:

Substances chimiques

MIRN324 microRNA, human 0
MIRN411 microRNA, human 0
MicroRNAs 0
Mirn337 microRNA, human 0
Nerve Growth Factor 9061-61-4
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Decree of Italian Ministry for Economical Progress 2018
ID : Project n°230 "Identification of new compounds for treatment of eye and ear diseases" to EA
Organisme : Dompé (Italy)
ID : 07_CONTRACT_DOMPE_TESSITORE for the project entitled 'MicroRNA expression analysis in response to different NGF bioformulations in in vitro corneal cell models' to AT

Références

Cell Mol Life Sci. 2001 May;58(5-6):748-59
pubmed: 11437236
Sci Rep. 2019 Oct 3;9(1):14272
pubmed: 31582785
Biochem Biophys Res Commun. 2009 Jan 9;378(2):259-63
pubmed: 19026611
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
PLoS One. 2011 Jan 17;6(1):e16132
pubmed: 21264230
PLoS One. 2014 Dec 09;9(12):e114692
pubmed: 25490205
PLoS One. 2013 Nov 26;8(11):e79926
pubmed: 24302991
Int J Mol Sci. 2018 Feb 04;19(2):
pubmed: 29401709
Nucleic Acids Res. 2018 Jan 4;46(D1):D239-D245
pubmed: 29156006
Exp Clin Endocrinol Diabetes. 2004 Oct;112(9):542-4
pubmed: 15505764
Invest Ophthalmol Vis Sci. 2014 Mar 13;55(3):1509-18
pubmed: 24474278
Invest Ophthalmol Vis Sci. 2020 May 11;61(5):7
pubmed: 32392315
Nat Cell Biol. 2011 Apr;13(4):423-33
pubmed: 21423178
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
Eye Brain. 2018 Jun 28;10:37-45
pubmed: 29988739
Transl Vis Sci Technol. 2020 Feb 07;9(3):5
pubmed: 32704425
Ann Intern Med. 2003 Oct 21;139(8):635-41
pubmed: 14568851
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):745-754
pubmed: 28146239
Cells. 2021 Mar 20;10(3):
pubmed: 33804633
Exp Eye Res. 2006 Apr;82(4):700-9
pubmed: 16289165
Arch Dis Child. 2002 Nov;87(5):446-8
pubmed: 12390930
Arch Ital Biol. 2011 Jun;149(2):283-92
pubmed: 21702001
Curr Neuropharmacol. 2015;13(3):294-303
pubmed: 26411962
J Transl Med. 2012 Nov 29;10:239
pubmed: 23190582
Ocul Surf. 2019 Jul;17(3):400-411
pubmed: 30959113
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6767-6775
pubmed: 27978558
NPJ Regen Med. 2021 Mar 26;6(1):16
pubmed: 33772031
Cancers (Basel). 2020 Jul 09;12(7):
pubmed: 32660045
Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4492-9
pubmed: 20357207
Invest Ophthalmol Vis Sci. 2013 Aug 09;54(8):5343-52
pubmed: 23833064
Int J Mol Sci. 2020 Jan 19;21(2):
pubmed: 31963809
Cells. 2020 Sep 26;9(10):
pubmed: 32993109
Nanotoxicology. 2018 May;12(4):312-324
pubmed: 29463199
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Am J Pathol. 2021 Nov;191(11):1974-1985
pubmed: 34390680
Curr Opin Ophthalmol. 2012 Jul;23(4):296-302
pubmed: 22543481
Ophthalmology. 2018 Sep;125(9):1468-1471
pubmed: 29653861
Invest Ophthalmol Vis Sci. 2012 Nov 01;53(12):7476-83
pubmed: 23049092
Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4323-9
pubmed: 17003422
N Engl J Med. 1998 Apr 23;338(17):1174-80
pubmed: 9554857
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6377-86
pubmed: 26444718
Sci Rep. 2018 Jul 9;8(1):10306
pubmed: 29985466
Invest Ophthalmol Vis Sci. 2016 Nov 01;57(14):6210-6222
pubmed: 27849309
J Cell Physiol. 2017 Apr;232(4):717-724
pubmed: 27683068
Anticancer Agents Med Chem. 2016;16(1):7-19
pubmed: 26299662
Exp Eye Res. 2020 Sep;198:108138
pubmed: 32712184
Eur J Immunol. 2011 Jul;41(7):2029-39
pubmed: 21469088
Lancet. 1999 Jul 24;354(9175):307
pubmed: 10440316
Mutat Res. 2011 Dec 1;717(1-2):85-90
pubmed: 21402084
PLoS One. 2012;7(10):e46957
pubmed: 23077538
Acta Pharmacol Sin. 2018 Jul;39(7):1073-1084
pubmed: 29877320
Ocul Surf. 2017 Oct;15(4):660-669
pubmed: 28483646
PLoS One. 2013 Dec 20;8(12):e84425
pubmed: 24376808
Ophthalmology. 2018 Sep;125(9):1332-1343
pubmed: 29653858
Mol Vis. 2012;18:758-64
pubmed: 22509106
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):692-702
pubmed: 10711683
Mol Med Rep. 2018 Sep;18(3):3203-3210
pubmed: 30066863
Ocul Surf. 2017 Jan;15(1):112-129
pubmed: 27789276
Br J Ophthalmol. 2020 Jan;104(1):127-135
pubmed: 30944103
Lancet. 2000 Nov 18;356(9243):1739-40
pubmed: 11095266
J Pharm Pharmacol. 2020 Dec;72(12):1732-1749
pubmed: 32783235
Cells. 2020 Jan 23;9(2):
pubmed: 31979244
Acta Ophthalmol. 2018 Feb;96(1):9-23
pubmed: 28271607
Exp Cell Res. 2017 Oct 1;359(1):10-16
pubmed: 28669664
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73
pubmed: 23680784
Tumour Biol. 2017 Jul;39(7):1010428317719577
pubmed: 28695771
Immunol Lett. 2012 Jan 30;141(2):165-8
pubmed: 22033216
Neural Regen Res. 2021 Sep;16(9):1740-1750
pubmed: 33510063
Exp Ther Med. 2021 Jun;21(6):599
pubmed: 33884037
Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2
pubmed: 10889110
Genomics Proteomics Bioinformatics. 2012 Oct;10(5):246-53
pubmed: 23200134
Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1063-9
pubmed: 10752942
Mol Ther Nucleic Acids. 2015 Sep 15;4:e252
pubmed: 26372022

Auteurs

Chiara Compagnoni (C)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.

Veronica Zelli (V)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Center for Molecular Diagnostics and Advanced Therapies, University of L'Aquila, Via Petrini, 67100 L'Aquila, Italy.

Andrea Bianchi (A)

Department of Information Engineering, Computer Science and Mathematics, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.

Antinisca Di Marco (A)

Department of Information Engineering, Computer Science and Mathematics, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.

Roberta Capelli (R)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.

Davide Vecchiotti (D)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Center for Molecular Diagnostics and Advanced Therapies, University of L'Aquila, Via Petrini, 67100 L'Aquila, Italy.

Laura Brandolini (L)

Dompé Farmaceutici Spa, via Campo di Pile, 1, 67100 L'Aquila, Italy.

Anna Maria Cimini (AM)

Department of Life, Health and Environmental Sciences, University of L'Aquila, P.zza S. Tommasi, 67100 L'Aquila, Italy.

Francesca Zazzeroni (F)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.

Marcello Allegretti (M)

Dompé Farmaceutici Spa, via Campo di Pile, 1, 67100 L'Aquila, Italy.

Edoardo Alesse (E)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.

Alessandra Tessitore (A)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Center for Molecular Diagnostics and Advanced Therapies, University of L'Aquila, Via Petrini, 67100 L'Aquila, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH